UBS Group Analysts Give Fresenius Medical Care AG & Co. KGaA (ETR:FME) a €92.00 Price Target

Share on StockTwits

UBS Group set a €92.00 ($106.98) target price on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research note published on Thursday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

FME has been the subject of several other reports. Credit Suisse Group set a €50.00 ($58.14) price objective on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a research report on Monday, May 6th. JPMorgan Chase & Co. set a €56.70 ($65.93) price objective on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Monday, June 24th. Nord/LB set a €92.00 ($106.98) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a buy rating in a research report on Friday, May 3rd. Jefferies Financial Group restated a buy rating and set a GBX 99 ($1.29) price objective on shares of in a research report on Friday, June 28th. Finally, Independent Research set a €74.00 ($86.05) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a neutral rating in a research report on Monday, June 17th. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has an average rating of Buy and an average price target of €82.57 ($96.01).

Shares of FME stock opened at €69.70 ($81.05) on Thursday. The stock’s 50 day moving average is €68.10. The company has a debt-to-equity ratio of 100.05, a current ratio of 1.02 and a quick ratio of 0.67. The firm has a market capitalization of $21.28 billion and a P/E ratio of 10.85. Fresenius Medical Care AG & Co. KGaA has a 12-month low of €55.44 ($64.47) and a 12-month high of €91.74 ($106.67).

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Read More: What is a stock buyback?

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.